- Home
- IONR vs XOMA Comparison
IONR vs XOMA Comparison
Compare IONR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- XOMA
- Stock Information
- Founded
- IONR 2001
- XOMA 1981
- Country
- IONR Australia
- XOMA United States
- Employees
- IONR N/A
- XOMA N/A
- Industry
- IONR
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- IONR
- XOMA Health Care
- Exchange
- IONR Nasdaq
- XOMA Nasdaq
- Market Cap
- IONR 319.2M
- XOMA 355.6M
- IPO Year
- IONR N/A
- XOMA N/A
- Fundamental
- Price
- IONR $5.23
- XOMA $26.76
- Analyst Decision
- IONR
- XOMA Strong Buy
- Analyst Count
- IONR 0
- XOMA 2
- Target Price
- IONR N/A
- XOMA $81.50
- AVG Volume (30 Days)
- IONR 51.6K
- XOMA 36.4K
- Earning Date
- IONR 01-01-0001
- XOMA 03-07-2025
- Dividend Yield
- IONR N/A
- XOMA N/A
- EPS Growth
- IONR N/A
- XOMA N/A
- EPS
- IONR N/A
- XOMA N/A
- Revenue
- IONR N/A
- XOMA $21,606,000.00
- Revenue This Year
- IONR N/A
- XOMA $511.48
- Revenue Next Year
- IONR N/A
- XOMA $26.91
- P/E Ratio
- IONR N/A
- XOMA N/A
- Revenue Growth
- IONR N/A
- XOMA 389.82
- 52 Week Low
- IONR $2.90
- XOMA $18.57
- 52 Week High
- IONR $9.35
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- IONR 66.61
- XOMA 47.49
- Support Level
- IONR $4.05
- XOMA $23.88
- Resistance Level
- IONR $4.58
- XOMA $29.02
- Average True Range (ATR)
- IONR 0.41
- XOMA 1.27
- MACD
- IONR 0.14
- XOMA 0.27
- Stochastic Oscillator
- IONR 86.78
- XOMA 56.03
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.